Alexis Borisy and Melanie Nallicheri (EQRx)
Fast follow: EQRx engineers $410M-plus worth of deals to CDK4/6, EGFR drugs
Alexis Borisy and Melanie Nallicheri have given the world a first glimpse at the markets they want to disrupt, as EQRx unveils the licensing of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
